| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue, net | 402,062 | 415,605 | 382,653 | 380,834 |
| Cost of goods sold | 195,071 | 206,273 | 188,221 | 180,596 |
| Research and development | 22,456 | 26,997 | 24,728 | 27,435 |
| Selling, general and administrative | 169,046 | 179,890 | 181,497 | 177,193 |
| Intangible asset amortization | 3,728 | 3,754 | 3,704 | 3,760 |
| Goodwill impairment charge | 0 | 511,365 | - | - |
| Total costs and expenses | 390,301 | 928,279 | 398,150 | 388,984 |
| Operating income (loss) | 11,761 | -512,674 | -15,497 | -8,150 |
| Interest income | 4,982 | 4,710 | 4,420 | 5,049 |
| Interest expense | 22,725 | 21,042 | 18,815 | 19,373 |
| Other (expense) income, net | -842 | -1,946 | -144 | 2,112 |
| Loss before income taxes | -6,824 | -530,952 | -30,036 | -20,362 |
| Benefit for income taxes | -1,420 | -46,879 | -4,743 | -9,667 |
| Net loss | -5,404 | -484,073 | -25,293 | -10,695 |
| Basic (in dollars per share) | -0.07 | -6.31 | -0.33 | -0.14 |
| Basic (in shares) | 76,753,000 | 76,695,000 | 76,463,000 | 76,448,000 |
| Diluted (in dollars per share) | -0.07 | -6.31 | -0.33 | -0.14 |
| Diluted (in shares) | 76,753,000 | 76,695,000 | 76,463,000 | 76,448,000 |
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)